AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 211 min read$NTHI

CHEN THOMAS C purchased $70K of NTHI (indirect holdings)

CHEN THOMAS C (CEO) purchased 12,757 indirectly-held shares of NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) at $5.49 on 2026-08-18.

Original reporting
SEC EDGAR · CHEN THOMAS C
Published Aug 21, 2026, 1:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 21, 2026, 1:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NTHI
Neutral
medium confidence
Mentioned
$NTHI
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTHINeutralLow
01

Why it matters

A small insider buy by the CEO may be viewed as a positive signal but is unlikely to affect the stock materially.

02

Market read

Limited relevance; primarily of interest to shareholders tracking insider activity.

03

What to watch

Potential upcoming corporate actions not disclosed could motivate the buy.

Relevance 4/10Novelty 4/10Timing: transaction dated 2026-08-18, filed 2026-08-20

Background

Form 4 filings disclose insider transactions; this is the first public report of this purchase.

Company-level read

Ticker impact

$NTHINeutralMedium confidence
Context

CEO Chen Thomas C purchased 12,757 shares for $69,998, increasing his stake to 13,705 shares.

Expected impact

Minimal short-term impact; may provide slight bullish bias.

Evidence & confidence

Purchase amount is under $100k for a micro‑cap, typical for 10b5‑1 plans, limited market effect.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Insider purchase may be routine; investors should not overreact.

Key entities

  • Company
    NeonC Technologies Holdings, Inc.

    Issuer of the Form 4 filing.

  • Person
    Chen Thomas C

    CEO and insider purchaser.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NTHI insider trading history →

Related articles

AUG 13
$NTHIMed

Stonegate, Inc.: Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NTHI) 2Q26

Stonegate Capital Partners updated coverage of NeOnc Technologies Holdings (NASDAQ: NTHI), citing 2Q26 progress for NEO100 and NEO212. NEO100 Phase 2a reported PFS at 6 months of 48.9% vs a 20% benchmark (p=0.0047), median OS 26.09 months, and no major toxicities. NeOnc plans a Type B FDA meeting; R&D rose to $2.6M from $0.7M year over year.

finanznachrichten.de4 min
AUG 12
$NTHIMed

WallStreet-PR: NeOnc's NEO100 Phase 2a Brain Cancer Study Beats Historical Benchmark by Nearly 2.5x

NeOnc Technologies Holdings (NASDAQ: NTHI) reported Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma. It said six-month progression-free survival was 48.9% versus a 20% historical benchmark, with p=0.0047. Median overall survival was about 26 months, with no major toxicities. NeOnc plans an FDA meeting on next trial steps.

finanznachrichten.de4 min
AUG 12
$NTHIMedAI 8/10

NeOnc Technologies Reports Positive Topline Data Of NEO100 Phase 2a Study, Stock Up In Pre-Market

NeOnc Technologies Holdings (NTHI) reported positive topline Phase 2a results for intranasal NEO100 (NEO100-01) in IDH1-mutant Grade IV glioma or Grade III astrocytoma. In 24 patients at 1,152 mg/day, six-month progression-free survival was 48.9% vs 20% expected. Median overall survival was 26.09 months. Company plans an FDA Type B meeting and will present full safety data.

rttnews.com4 min
AUG 12
$NTHIHighAI 9/10

Why is Neonc Technologies stock surging today?

Investing.com reports Neonc Technologies Holdings Inc (NTHI) shares rose 11.3% pre-open after its Phase 2a NEO100-01 intranasal NEO100 study in Grade III/IV IDH1-mutant glioma met the primary endpoint. Six-month progression-free survival was 48.9% vs a 20% benchmark (p=0.0047) in 24 patients. Company discussed efficacy, safety, and next regulatory steps.

investing.com4 min
AUG 12
$NTHIMedAI 8/10

NeOnc Technologies stock jumps on positive glioma trial data

NeOnc Technologies Holdings (NASDAQ:NTHI) shares rose 11.7% after positive topline Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma. The study met its primary endpoint with 6-month progression-free survival of 48.9% vs a 20% benchmark (p=0.0047). Median overall survival was 26.09 months; 86.7% were alive at six months. The company plans an FDA Type B meeting.

investing.com4 min